title: Therapeutic effect of cytomedicine on mesangio-proliferative glomerulonephritis in human interleukin-6 transgenic mice.
abstract: We previously demonstrated that IgG1 plasmacytosis in human interleukin-6 transgenic mice (hIL-6 Tgm) was suppressed by the implantation of SK2 hybridoma cells (SK2 cells, which secrete anti-hIL-6 monoclonal antibodies) microencapsulated in a semipermeable and biocompatible device. In this study, we demonstrated that the mesangio-proliferative glomerulonephritis in hIL-6 Tgm was also improved by the same treatment. These results strongly support the concept of cytomedicine, which is a novel drug delivery system (DDS) using living cells. However, an electron microscopy study showed that cytomedicine has a limited duration of effectiveness because of the disappearance of space for cell proliferation in the microcapsule. Thus, the control of cell proliferation in a device must be developed to prolong the function and effectiveness of cytomedicine.
authors.affiliation: Faculty of Pharmaceutical Sciences, Osaka University, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Okada
authors.forename: H
authors.initials: H
authors.lastname: Miyamoto
authors.forename: T
authors.initials: T
authors.lastname: Yoshioka
authors.forename: A
authors.initials: A
authors.lastname: Katsume
authors.forename: H
authors.initials: H
authors.lastname: Saito
authors.forename: K
authors.initials: K
authors.lastname: Yorozu
authors.forename: O
authors.initials: O
authors.lastname: Ueda
authors.forename: S
authors.initials: S
authors.lastname: Nakagawa
authors.forename: Y
authors.initials: Y
authors.lastname: Ohsugi
authors.forename: T
authors.initials: T
authors.lastname: Mayumi
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D001806:Blood Urea Nitrogen; D002460:Cell Line; D004339:Drug Compounding; D016503:Drug Delivery Systems; D005260:Female; D005920:Glomerular Mesangium / Q000473:pathology*; D015432:Glomerulonephritis, Membranoproliferative / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D020136:Hydrogel, Polyethylene Glycol Dimethacrylate; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000627:therapeutic use*; D015850:Interleukin-6 / Q000096:biosynthesis* / Q000235:genetics; D008567:Membranes, Artificial; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D011092:Polyethylene Glycols; D011507:Proteinuria / Q000188:drug therapy
chemical_list: D000911:Antibodies, Monoclonal; D007074:Immunoglobulin G; D015850:Interleukin-6; D008567:Membranes, Artificial; D020136:Hydrogel, Polyethylene Glycol Dimethacrylate; D011092:Polyethylene Glycols